| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00117-008-1784-9 |
| P698 | PubMed publication ID | 19296068 |
| P2093 | author name string | K Scheidhauer | |
| F C Gaertner | |||
| M Miederer | |||
| P2860 | cites work | Imaging of neuroendocrine tumors | Q28245029 |
| Evaluation of Positron Emission Tomography Imaging Using [68Ga]-DOTA-D Phe1-Tyr3-Octreotide in Comparison to [111In]-DTPAOC SPECT. First Results in Patients with Neuroendocrine Tumors | Q34542072 | ||
| Functional imaging of neuroendocrine tumours with PET. | Q36621478 | ||
| Nuclear imaging of neuroendocrine tumours | Q36768664 | ||
| Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors | Q43690572 | ||
| 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. | Q44779847 | ||
| Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT. | Q46354494 | ||
| Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors | Q46443851 | ||
| Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival | Q46619794 | ||
| Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role | Q47770029 | ||
| 99mTc-EDDA/HYNIC-Tyr(3)-octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors. | Q51840066 | ||
| Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients. | Q53503895 | ||
| [Positron emission tomography (PET) in gastrointestinal cancer]. | Q53531661 | ||
| Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide. | Q53543895 | ||
| 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours: first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives | Q57757828 | ||
| Receptor scintigraphy in endocrine gastrointestinal and pancreatic tumors | Q67518221 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | German | Q188 |
| P304 | page(s) | 217-223 | |
| P577 | publication date | 2009-03-01 | |
| P1433 | published in | Radiologe | Q15763177 |
| P1476 | title | [PET-CT for neuroendocrine tumors and nuclear medicine therapy options]. | |
| P478 | volume | 49 |
| Q38191823 | Clinical approach to the patient with a solid pancreatic mass |
| Q43879292 | Comparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas |
| Q85050851 | Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy |
| Q85335897 | [Gastroenteropancreatic endocrine tumors] |
Search more.